Vivoryon Therapeutics (Netherlands) Today
| VVY Stock | 2.04 0.01 0.49% |
Performance0 of 100
| Odds Of DistressOver 65
|
Vivoryon Therapeutics is selling for under 2.04 as of the 22nd of November 2024; that is 0.49 percent up since the beginning of the trading day. The stock's lowest day price was 1.99. Vivoryon Therapeutics has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Vivoryon Therapeutics NV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Moving together with Vivoryon Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Vivoryon Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vivoryon Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vivoryon Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Vivoryon Therapeutics NV (VVY) is traded on Euronext Amsterdam in Netherlands and employs 14 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 365.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vivoryon Therapeutics's market, we take the total number of its shares issued and multiply it by Vivoryon Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vivoryon Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 24.11 M outstanding shares.
Vivoryon Therapeutics generates negative cash flow from operations
Check Vivoryon Therapeutics Probability Of Bankruptcy
Ownership AllocationVivoryon Therapeutics shows a total of 24.11 Million outstanding shares. Vivoryon Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vivoryon Ownership Details
Vivoryon Therapeutics Risk Profiles
Although Vivoryon Therapeutics' alpha and beta are two of the key measurements used to evaluate Vivoryon Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.82 | |||
| Semi Deviation | 4.42 | |||
| Standard Deviation | 5.24 | |||
| Variance | 27.44 |
Vivoryon Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vivoryon Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Watchlist Optimization Now
Watchlist OptimizationOptimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
| All Next | Launch Module |
Vivoryon Therapeutics Corporate Management
Elected by the shareholders, the Vivoryon Therapeutics' board of directors comprises two types of representatives: Vivoryon Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vivoryon. The board's role is to monitor Vivoryon Therapeutics' management team and ensure that shareholders' interests are well served. Vivoryon Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vivoryon Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Florian Schmid | CFO Board | Profile | |
| Manuela Bader | Director Communications | Profile | |
| Konrad Glund | CoFounder Advisor | Profile | |
| Michael Schaeffer | Chief Board | Profile | |
| Ulrich Dauer | Chairman CEO | Profile | |
| Frank MD | Chief Officer | Profile | |
| Hendrik Liebers | Advisor | Profile |
Additional Tools for Vivoryon Stock Analysis
When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.